
Lexeo Therapeutics Jumps 12.5% on Positive Interim Heart-Disease Gene Therapy Data
The company also reported third-quarter results and said the FDA is open to using non-sustained ventricular tachycardia as a primary endpoint for a pivotal study.
Lexeo Therapeutics, Inc. · Nasdaq · Biological Products, (No Diagnostic Substances)

The company also reported third-quarter results and said the FDA is open to using non-sustained ventricular tachycardia as a primary endpoint for a pivotal study.
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Nov. 17, 2026 | Louis Edward Tamayo Chief Financial Officer | Sold | 1,007 | $3.26 | $3,283 |
| Nov. 17, 2026 | Jose Manuel Otero Chief Operating Officer | Sold | 1,285 | $3.26 | $4,189 |
| Nov. 17, 2026 | Richard Nolan Townsend Chief Executive Officer, director | Sold | 3,295 | $3.26 | $10,742 |
| Aug. 18, 2026 | Louis Edward Tamayo Chief Financial Officer | Sold | 4,117 | $4.91 | $20,203 |
| Aug. 18, 2026 | Richard Nolan Townsend Chief Executive Officer, director | Sold | 3,345 | $4.95 | $16,562 |
| Aug. 18, 2026 | Jose Manuel Otero Chief Operating Officer | Sold | 1,304 | $4.96 | $6,464 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Results of operations and financial condition · Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedLexeo Therapeutics Q3 2026 net loss of $0.43 per share misses $0.32 consensus, while LX2020 interim data show 80% NSVT reduction